Skip to content

Medical-device intelligence

SBA: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate

FDA product code SBA: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
SBA
FDA device name
Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate
Device class
2
Regulation number
862.1357
Medical specialty
Clinical Chemistry
Review panel
CH

FDA definition

An integrated continuous glucose monitoring system (iCGM) with sensor containing dexamethasone acetate is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time. iCGM systems are designed to reliably and securely transmit glucose measurement data to digitally connected devices, including automated insulin dosing systems, and are intended to be used alone or in conjunction with these digitally connected medical devices for the purpose of managing a disease or condition related to glycemic control. The dexamethasone acetate coating is intended to reduce inflammation at the sensor insertion site.
Explore clinical chemistry records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

1 clearance records and 0 recall records in the covered releases, across 1 source company names and 1 product codes. Dated history runs from Sep 16, 2024 to Sep 16, 2024.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

1 matching records
Device / recordCompany in FDA recordSourceSource date
Eversense 365 Continuous Glucose Monitoring (CGM) SystemK241335 · SBASenseonics, Incorporated510(k)Sep 16, 2024FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗